Luqman Olaoye

Luqman Olaoye

Auto-generated profile, based on publicly available information

Luqman Olaoye

Department of Chemistry and Forensic Science, School of Science and Technology, Nottingham Trent University, Clifton Lane, Nottingham, NG11 8NS, United Kingdom

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2024 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
LOLuqman Olaoye
Luqman Olaoye
ASAzad Sedeeq Sadraddin
Azad Sedeeq Sadraddin
SBShwana ahmed BRAIM
Shwana ahmed BRAIM
Objective: This study aims to develop a novel smart formulation based on dual-responsive Polyethylene Glycol Methacrylate-Grafted-Chitosan (PEGMA-g-Cs) copolymers for the controlled delivery of Lactoferrin. The goal is to enhance the bioavailability and therapeutic efficacy of Lactoferrin in treating colorectal cancer, addressing its rapid degradation in a highly acidic gastric environment. Methods: Gold-coated Superparamagnetic Iron Oxide Nanoparticles (Au-SPIONs) were synthesized and loaded into PEGMA-g-Cs microspheres. Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), Proton Nuclear Magnetic Resonance (HNMR), X-Ray Diffraction (XRD), Infrared Spectroscopy (IR), UV-visible spectrophotometry (UV-Vis), optical microscopy, and Dynamic Light Scattering (DLS) were used to characterise the synthesized materials. Drug loading and release studies of lactoferrin-loaded microbead formulations were conducted to evaluate encapsulation efficiency, loading capacity, and release profiles. Results: The lactoferrin-loaded microbead formulations demonstrated excellent encapsulation efficiency and loading capacity. Specifically, Encapsulation Efficiency (EE) was 77% and Loading Capacity (LC) was 4.99% for the homogenizer batch, while the magnetic stirring batch achieved 86% EE and 3.12% LC. The formulation exhibited minimal release (<20%) in Simulated Gastric Fluid (SGF) and almost complete release in Simulated Colonic Fluid (SCF). The 3-[4,5-Dimethylthiazol-2-Yl]-2,5-Diphenyl Tetrazolium Bromide (MTT) cell cytotoxicity assay in human CaCo-2 colon cancer cells revealed a significant reduction in cell proliferation following treatment with the new formulations. Conclusion: The findings suggest that the new formulation can be a promising approach for the targeted delivery of Lactoferrin, thereby improving the efficacy of colorectal cancer treatment by enhancing the bioavailability of lactoferrin.